Runimotamab - Genentech
Alternative Names: BTRC-4017A; HER2/CD3 TDB; RG-6194; RO-7227780Latest Information Update: 04 Jul 2025
At a glance
- Originator Genentech
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Gastric cancer; Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacokinetics, pharmacodynamics,adverse events and efficacy data from a phase I trial in Solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 26 Feb 2025 Discontinued - Phase-I for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, Netherlands, Taiwan, Singapore, South Korea, Japan, Italy, France, Denmark, Canada, Belgium (IV) (Roche pipeline, February 2025)
- 26 Feb 2025 Discontinued - Phase-I for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in United Kingdom (IV) (Roche pipeline, February 2025)